BVX - Bovie Medical Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
5.57
-0.40 (-6.70%)
As of 3:55PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close5.97
Open6.00
Bid5.70 x 1000
Ask5.70 x 1100
Day's Range5.50 - 6.08
52 Week Range2.28 - 7.70
Volume212,214
Avg. Volume165,758
Market Cap184.944M
Beta (3Y Monthly)-0.75
PE Ratio (TTM)2.81
EPS (TTM)1.98
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.88
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Bovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Tara H. Semb as Chief Financial Officer, effective January 2, 2019. “I am pleased to announce the appointment of Tara Semb, who joins the executive leadership team at Bovie Medical with a strong background in financial and operational business process and internal controls,” said Charlie Goodwin, President and Chief Executive Officer. “Ms. Semb’s career history includes executive level experience as the Chief Financial Officer for a rapidly growing company in the consumer market, and she has also held senior positions on the finance team at a large, diversified global manufacturing company with significant commercial scale and profitability.

  • Business Wire6 days ago

    Bovie Medical Corporation Announces Corporate Name Change to Apyx Medical Corporation and Plans to Transition Common Stock Listing to NASDAQ Global Select Market

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced a corporate rebranding and company name change to Apyx Medical Corporation effective January 1, 2019. The Company also announced plans to move its stock exchange listing to the NASDAQ Global Select Market (the “NASDAQ”) from the New York Stock Exchange (the “NYSE”). The Company expects that its common stock will commence trading on the NASDAQ Global Select Market on January 2, 2019, under a new ticker symbol – “APYX”.

  • Zacks6 days ago

    Quidel (QDEL) Catches Eye: Stock Jumps 6.7%

    Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.

  • Zacks6 days ago

    Why Varex Imaging (VREX) Could Be Positioned for a Slump

    Varex Imaging (VREX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • GuruFocus.com11 days ago

    5 Stocks Join Ben Graham Net-Net Screener in Market Decline

    Stocks becoming more attractive buys

  • Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
    Zacks12 days ago

    Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

    Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

  • Will Bovie Medical (BVX) Continue to Surge Higher?
    Zacks18 days ago

    Will Bovie Medical (BVX) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Bovie Medical Corporation (BVX).

  • Business Wirelast month

    Bovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary, intends to retire. The Company has initiated a search for a new Chief Financial Officer and Mr. Ewers is committed to remaining in his current role until a successor is found. “I would like to thank Jay, on behalf of the Board and the entire team at Bovie Medical, for his significant contributions since joining the Company in 2014,” said Charlie Goodwin, President and Chief Executive Officer.

  • What Makes Bovie Medical (BVX) a Strong Momentum Stock: Buy Now?
    Zackslast month

    What Makes Bovie Medical (BVX) a Strong Momentum Stock: Buy Now?

    Does Bovie Medical (BVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Associated Press2 months ago

    Bovie: 3Q Earnings Snapshot

    On a per-share basis, the Clearwater, Florida-based company said it had profit of $1.98. Losses, adjusted to account for discontinued operations, came to 1 cent per share. The medical device maker posted ...

  • Business Wire2 months ago

    Bovie Medical Corporation Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Outlook

    Advanced Energy Sales of $3.0 million in Q3, up 40% year-over-year and 92% year-to-date

  • Business Wire2 months ago

    Bovie Medical Corporation to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

    Bovie Medical Corporation , a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the 9th Annual Craig-Hallum Alpha Select Conference at the Sheraton New York Times Square Hotel in New York, New York.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Appointment of Laura Iversen as Director of Global Operations for Advanced Energy

    Bovie Medical Corporation (BVX) (the “Company”), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Laura Iversen as Director of Global Operations for Advanced Energy. “Bovie Medical is pleased to announce the appointment of Laura Iversen to this newly created leadership position, as we continue to focus on improving our manufacturing capabilities and efficiencies to accommodate the strong demand that we anticipate for our Advanced Energy products in the years to come,” said Charlie Goodwin, Chief Executive Officer of the Company.

  • Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition
    Zacks2 months ago

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

  • Snap Up These 5 Stocks on New Analyst Coverage
    Zacks2 months ago

    Snap Up These 5 Stocks on New Analyst Coverage

    Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

  • Simply Wall St.2 months ago

    Are Bovie Medical Corporation’s (NYSEMKT:BVX) Interest Costs Too High?

    While small-cap stocks, such as Bovie Medical Corporation (NYSEMKT:BVX) with its market cap of US$213m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Implied Volatility Surging for Bovie Medical (BVX) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Bovie Medical (BVX) Stock Options

    Bovie Medical (BVX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?
    Zacks2 months ago

    Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?

    Investors need to pay close attention to Bovie Medical (BVX) stock based on the movements in the options market lately.

  • Business Wire2 months ago

    Bovie Medical Corporation to Release Third Quarter of Fiscal Year 2018 Financial Results on November 1, 2018

    Bovie Medical (BVX), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the third quarter of fiscal year 2018 will be released after the market closes on Thursday, November 1. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 6375776. Participants should ask for the Bovie Medical Corporation Call.

  • Business Wire3 months ago

    Bovie Medical Corporation to Present at the Sidoti & Company Fall 2018 Investor Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the Sidoti & Company Fall 2018 Investor Conference at the Grand Hyatt in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/.

  • Business Wire3 months ago

    Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today updated financial guidance expectations for the twelve months ending December 31, 2018. The Company is introducing fiscal year 2018 financial guidance on a continuing operations basis as adjusted, which reflects the consummation of the Core segment sale transaction which closed on August 30, 2018. Total revenue from continuing operations in the range of $15.2 million to $15.6 million, representing growth of 49% to 53% year-over-year, compared to total revenue from continuing operations of $10.2 million in fiscal year 2017.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Completion of “Core” Business Segment Sale to Symmetry Surgical, Inc. for Total Cash Consideration of $97 Million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that it has completed the previously announced divestiture and sale of the Core business segment and the Bovie® brand to Symmetry Surgical, Inc. for gross proceeds of $97 million in cash. Bovie Medical shareholders voted to approve the divestiture and sale transaction at an annual meeting of shareholders held on August 30, 2018.

  • Associated Press5 months ago

    Bovie: 2Q Earnings Snapshot

    On a per-share basis, the Clearwater, Florida-based company said it had a loss of 1 cent. The medical device maker posted revenue of $11.5 million in the period. In the final minutes of trading on Wednesday, ...

  • Business Wire5 months ago

    Bovie Medical Corporation Reports Second Quarter 2018 Financial Results

    Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year